Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma.
The aim of this study was to evaluate serum calprotectin levels and oxidative stress status in patients with papillary thyroid carcinoma (PTC) and the changes in their levels after total thyroidectomy. The study involved 30 patients with PTC and 30 healthy controls. Blood samples were obtained from the PTC patients before and 1 month after the operation. Preoperative and postoperative serum samples from PTC patients and healthy controls were analysed for calprotectin, total antioxidant status (TAS), total oxidant status (TOS) and lipid hydroperokside (LOOH). The preoperative calprotectin, TOS, OSI and LOOH levels of the patients with PTC were significantly higher compared to those of the control group (p < 0.001, for each). The levels of calprotectin decreased significantly in patients with PTC after the operation (p < 0.001), while TAS, TOS and OSI levels remained unchanged (p = 0.313, p = 0.085 and p = 0.163, respectively). Preoperative serum calprotectin levels were positively correlated with TOS, OSI and LOOH levels and negatively correlated with TAS levels in patients with PTC. In conclusion, serum calprotectin levels is increased in patients with PTC, and calprotectin is positively correlated with TOS and LOOH. Serum calprotectin levels is significantly decreased after total thyroidectomy.
Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
S
S
Tabur
Edirne State Hospital, Endocrinology and Metabolic Disease, 22030, Edirne, Turkey. drhkorkmaz@yahoo.com.tr.
H
H
Korkmaz
Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
M
M
Özkaya
Department of Nuclear Medicine, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
U
U
Elboğa
Department of Clinical Biochemistry, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
M
M
Tarakçıoglu
Department of Clinical Biochemistry, Faculty of Medicine, Harran University, 63300, Sanliurfa, Turkey.
N
N
Aksoy
Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Gaziantep University, 27100, Sahinbey, Gaziantep, Turkey.
E
E
Akarsu
D000328:Adult; D000975:Antioxidants / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000097:blood* / Q000378:metabolism; D002291:Carcinoma, Papillary / Q000097:blood* / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D039841:Leukocyte L1 Antigen Complex / Q000097:blood*; D008054:Lipid Peroxides / Q000378:metabolism; D008055:Lipids / Q000502:physiology; D008297:Male; D016877:Oxidants / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology; D000077273:Thyroid Cancer, Papillary; D013961:Thyroid Gland / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000097:blood* / Q000378:metabolism
D000975:Antioxidants; D014408:Biomarkers, Tumor; D039841:Leukocyte L1 Antigen Complex; D008054:Lipid Peroxides; D008055:Lipids; D016877:Oxidants
Calprotectin; Oxidative stress; Thyroid papillary carcinoma